Mm1 (Mm1)
Finasteride Tablet, Film Coated
Product Images NDC 76282-412
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 76282-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Mm2)
The text describes a figure (Figure 1) that shows the Symptom Score in a long-term study. There are two groups displayed (Placebo and Finasteride) with their corresponding mean change from baseline over the years (Year 1, Year 2, Year 3, and Year 4). There are also some numerical values for each group and year.*
Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Mm3)
This is a figure displaying the percentage of patients undergoing surgery for benign prostatic hyperplasia (BPH), including transurethral resection of the prostate (TURP) over time. The graph compares the outcomes of a group treated with finasteride to a group that received a placebo. The X-axis depicts the months of observation, while the Y-axis indicates the percentage of patients undergoing BPH surgery. The cumulative number of events and the number at risk per year are provided for both groups.*
Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Mm4)
This appears to be a graph (Figure 3) showing the percentage of patients developing acute urinary retention due to the medication finasteride versus placebo. The x-axis displays the time (in weeks) and the y-axis displays the percentage of patients affected. The finasteride group had a lower percentage of patients affected compared to the placebo group. The graph also provides additional statistics for both groups, including the number of events and number at risk per year.*
Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Mm5)
This is a graph or figure showing the changes in prostate volume in a long-term study measuring efficacy and safety. The data is presented over the course of 4 years with a baseline measurement and measurements taken at years 1, 2, 3, and 4. There are two groups: a placebo group and a group taking finasteride. The finasteride group had fewer events cumulatively which are not defined in the text, and the number of participants at risk decreased each year.*
5mg-90 (Mm6)
Mm7
This is a medication label for Finasteride tablets, USP manufactured by Ascent Pharmaceuticals Inc, prescribed to be taken orally once a day at a 5mg dose. Finasteride is not recommended for use by women or children and additional caution should be taken by pregnant women or women who may be pregnant. Each bottle contains 90 film-coated tablets and should be stored at room temperature (20°C to 25°C), away from light, and kept tightly closed. Please see the patient information leaflet for more information.*
Mm8
The text contains information regarding a medication called Finasteride. It is in tablet form and each tablet contains 5mg of Finasteride USP. It is meant for adult use only and should be taken once a day. The medication should be stored at room temperature away from light and must not be handled by women who are pregnant or may become pregnant. The manufacturer of the medication is InvaGen Pharmaceuticals, Inc, and it is distributed by Exelan Pharmaceuticals, Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
